Summary
Twenty-one hypertensive patients were treated orally with 50mg gallopamil in a sustained-release formulation once daily for 1 week. 11 patients had a normal liver function (antipyrine clearance 41.2 ± 2.8 ml/min; mean ± SD), while 10 patients had fatty liver disease (antipyrine clearance 32.3 ± 1.4 ml/min). Maximum plasma concentrations of gallopamil were 15.2 (7.9 to 29.3) µg/L (geometric mean; 95% confidence interval) in patients with normal and 16.8 (8.7 to 32.5) µg/L in those with impaired hepatic function (p > 0.05). The elimination half-life was 8.8 hours in patients with normal liver function and 9.2 hours in patients with fatty liver disease (median, p > 0.05). No significant differences were found between patients with and without concomitant liver disease with regard to the effects of gallopamil on heart rate, PQ-time and blood pressure. First degree AV-block developed during treatment with gallopamil in one patient with fatty liver disease and in another with normal liver function. The AV-block in the patient with impaired hepatic function was considered to be severe (PQ-time 270ms). In conclusion, kinetic parameters of patients with fatty liver disease did not differ significantly from those of subjects with normal liver function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brogden RN, Benfield P. Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease. Drugs 1994; 47: 93–115
Eichelbaum M. Pharmakokinetik und Metabolismus von Gallopamil. Zeitschrift für Kardiologie 1989; 78 Suppl. 5: 20–4
Stieren B, Bühler V, Hege HG, et al. Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M, Hopf R, editors. Gallopamil, pharmacological and clinical profile of a calcium antagonist. Berlin: Springer, 1984: 88–93
Eichelbaum M, Mikus G. Pharmacokinetics, bioavailability, cardiovascular and biochemical effects of gallopamil in patients with liver cirrhosis and in healthy subjects without liver disease. Internal Report, Dr M. Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany, 1992: 1–9
Kaim AAH, Farker K. Pharmacokinetics and pharmacodynamics of gallopamil in patients with liver cirrhosis [abstract no. 36]. Naunyn Schmiedebergs Arch Pharmacol 1992; 345 Suppl.: R9
Mensink CK, Hempenius J, Wilkens G, et al. Determination of gallopamil and norgallopamil in human plasma by high performance liquid chromatography and fluorescence detection. Description and validation of assay method. Internal Report, Pharma Bio-Reasearch International, Zuidlaren, Netherlands, 1990
Eichelbaum M, Somogyi A. Rapid and sensitive method for the determination of antipyrine in biological fluids by high pressure liquid chromatography. J Chromatogr 1977; 140: 288–92
Sachs L. Angewandte Statistik. 7th ed. Berlin: Springer, 1992
Dylewicz P, Kirch W, Santos SR, et al. Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 1987; 32: 563–8
Kleinbloesem CH, Van Harten J, Wilson JPH, et al. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after i.v. and oral administration. Clin Pharmacol Ther 1986; 40: 21–8
Lasseter KC, Shambleu EC, Murdoch AA, et al. Steady state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 1984; 6 Suppl. 7: 977–81
Somogyi A, Albrecht M, Kliems G, et al. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981; 12: 51–60
Branch RA, James J, Read AE. A study of factors influencing drug disposition in chronic liver disease, using the model (+)-propranolol. Br J Clin Pharmacol 1976; 3: 243–9
Kirch W, Rose I, Demers HG, et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110–3
Kirch W, Halabi A, Nokhodian A. Disposition and elimination of bunazosin in chronic liver disease and renal insufficiency. Eur J Drug Metab Pharmacokinet 1993; 18: 309–13
Vesell ES, Passananti GT, Glenwright PA, et al. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva and urine. Clin Pharmacol Ther 1975; 18: 259–72
Andreasen PB, Ranek L, Statland BE, et al. Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest 1974; 4: 129–34
Andreasen PB, Vesell ES. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther 1974; 16: 1059–65
Williams RL, Schary WL, Blaschke TF, et al. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clin Pharmacol Ther 1976; 20: 90–7
Shull HJ, Wilkinson GR, Johnson R, et al. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976; 84: 420–5
Kirch W, Ohnhaus EE, Dylewicz P, et al. Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. Am Heart J 1986; 111: 325–9
Storstein L. Studies on digitalis II — The influence of renal function on the renal excretion of digitoxin and its cardioactive metabolites. Clin Pharmacol Ther 1974; 16: 25–34
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siepmann, M., Rao, B.R. & Kirch, W. Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease. Clin. Drug Invest. 10, 337–343 (1995). https://doi.org/10.2165/00044011-199510060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199510060-00004